ArticleProceedings of the National Academy of Sciences of the United States of America2024
Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization.
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bibliometric analysis combined with visualization on universal trends and hot topics of LOX family in human diseases: 1995 to 2025.Frontiers in oncology · 2025Pooled it
- Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.British journal of cancer · 2026Article
- Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment.Prostate cancer and prostatic diseases · 2026Article
- LAMP2 drives M2 macrophage polarization and promotes glioma progression through autophagy.Discover oncology · 2026Article
- Article
- Multidimensional explanations and future perspectives on the limited efficacy of immunotherapy in prostate cancer.Asian journal of andrology · 2026Review
- scRNA-seq and genomics analyses reveal key mechanisms of inverted papilloma-associated sinonasal squamous cell carcinoma malignant transformation.bioRxiv : the preprint server for biology · 2026Article
- Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post-Operative Osteosarcoma Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- An orally bioavailable pan-αv/α5β1 integrin antagonist prevents aggressive prostate cancer progression via suppressing both oncogenic signals and CD47-mediated immune escape.Molecular cancer · 2026Article
- CD18-targeted peptide-drug conjugate remodels the immunosuppressive tumor microenvironment of prostate cancer by selective depletion of M2 macrophages.NPJ precision oncology · 2026Article
- Intercellular Horizontal Transfer of TXNDC5 mRNA via Extracellular Vesicles Contributes to Tumor-Associated Macrophage-Mediated Prostate Cancer Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Single-cell RNA sequencing of adenoid cystic carcinoma of the breast reveals cellular heterogeneity and tumor microenvironment features.BMC medical genomics · 2026Article
- Targeting urological cancers with CAR-T cell therapy: current landscape and future directions.Journal of translational medicine · 2026Review
- PEAK1 promotes prostate cancer progression and docetaxel resistance by mediating the polarization of tumor-associated macrophages.European journal of medical research · 2026Article
- The Spatiotemporal Heterogeneity of Tumor-Associated Stromal Cells: Reprogramming Plasticity to Unlock Precision Cancer Immunotherapy.Cancer communications (London, England) · 2026Review
- The Role of Distinct Cancer-Associated Fibroblast Subtypes in Prostate Cancer Immunotherapy.International journal of biological sciences · 2026Review
- Review
- Immune checkpoint inhibition in bone metastases: lesion response heterogeneity, the osteoimmune niche, and microenvironment-directed therapy.Frontiers in immunology · 2026Review
- Characteristics and therapeutic resistance mechanisms of the prostate cancer immune microenvironment: a comprehensive analysis from bench to clinic.Frontiers in pharmacology · 2026Review
- Research advances in the role of osteoblasts and their derivatives in the development, recurrence, and distant metastasis of malignant bone tumors: a narrative review.EFORT open reviews · 2025Review
Corrections and comments
- Update of
Authors and funding
16 authors.
Guoyu Yu *Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0003-3030-5983
Paul G Corn *Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Celia Sze Ling Mak *Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Xin LiangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Miao ZhangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Patricia TroncosoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0002-8241-1430
Jian H SongDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0001-9252-1468
Song-Chang LinDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0003-1763-1303
Xingzhi SongDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Jingjing LiuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Jianhua ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Marites P MelanconDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Theocharis PanaretakisDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Guocan WangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Sue-Hwa LinDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MTargeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4MEndothelial-to-osteoblast transition in prostate cancer bone metastasisR01CA174798 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, SUE-HWA · 2013 to 2023
$3.0MCis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progressionR01CA276235 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Guocan Wang · 2023 to 2026
$1.5MThe Science of Really Gross Things: Engaging Young Learners in Biomedical ScienceR25OD010522 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HEINZ, JASON · 2012 to 2015
$846kCancer Prevention and Research Institute of Texas (CPRIT) RP230247DOD | USA | MEDCOM | CDMRP | DOD Prostate Cancer Research Program (PCRP) DOD-PCRP-Idea W81XWH-21-1-0522HHS | NIH | National Cancer Institute (NCI) 5P50CA140388HHS | NIH | National Cancer Institute (NCI) CA276235-01HHS | NIH | National Cancer Institute (NCI) R01CA174798NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA140388NCI NIH HHS R01 CA174798NCI NIH HHS R01 CA276235
Abstract
Immune checkpoint therapy has limited efficacy for patients with bone-metastatic castration-resistant prostate cancer (bmCRPC). To improve immunotherapy for bmCRPC, we aimed to identify the mechanism of bmCRPC-induced changes in the immune microenvironment. Among bmCRPC patients, higher levels of a 32-gene M2-like macrophage signature in bone metastasis samples correlated with shorter overall survival. Immunohistochemistry showed that CD206-positive (CD206
Indexed as
Bone NeoplasmsEndothelial CellsMacrophagesOsteoblastsTumor MicroenvironmentWnt Signaling PathwayAnimalsCell Line, TumorHumansMaleMiceProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantTumor-Associated Macrophagesbone metastasisEC-to-OSB transitionmacrophageprostate cancertumor-induced bone
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.